Welcome to our dedicated page for Semler Scientific SEC filings (Ticker: SMLR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Semler Scientific, Inc. (Nasdaq: SMLR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents cover both its healthcare operations and its Bitcoin treasury activities, offering investors insight into how the company reports revenues and expenses from its medical device and software business alongside unrealized gains and losses from changes in the fair value of its Bitcoin holdings.
In its periodic reports, Semler Scientific presents financial statements that reflect income from operations in its healthcare segment, operating expenses such as engineering and product development, sales and marketing, and general and administrative costs, as well as line items related to digital assets. The filings detail the fair value of Bitcoin classified as intangible digital assets, changes in that fair value, and the impact on pre-tax income. They also describe capital-raising transactions, including at-the-market equity offering programs and 4.25% convertible senior notes due 2030, and provide information on stockholders’ equity.
Current reports on Form 8-K document material events such as the adoption and evolution of Semler Scientific’s Bitcoin treasury strategy, the master loan agreement with Coinbase Credit Inc. secured by Bitcoin collateral, and the agreement in principle to settle a civil investigative demand from the U.S. Department of Justice. Other 8-K filings describe a strategic plan to realign operations through headcount reductions and expense curtailment, a non-executive retention program, executive officer changes and the Agreement and Plan of Merger providing for the acquisition of Semler Scientific by Strive, Inc. in an all-stock transaction.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify items such as segment performance, digital asset disclosures, capital structure changes and merger-related information. Investors can also use the filings to monitor topics like BTC Yield as a disclosed key performance indicator, the structure of Bitcoin-related financing arrangements and other regulatory disclosures relevant to SMLR.
Semler Scientific filed a communication under Rule 425 noting that its Executive Chairman and Director of Bitcoin Strategy retweeted posts about the proposed acquisition of Semler Scientific by Strive, Inc.
Strive has filed a Registration Statement on Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement of Strive, a proxy statement of Semler Scientific, and a prospectus of Strive. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek approval of the proposed transaction.
The companies direct investors to obtain the Registration Statement and related documents from the SEC and company websites. The communication states it is not an offer or solicitation, and includes customary forward‑looking statement cautions.
Semler Scientific announced an administrative update to its planned all-stock acquisition by Strive, Inc.. The company furnished an 8‑K with Exhibit 99.1, providing supplemental disclosures about Strive in connection with the merger agreed on
The update notes that Strive has filed a Form S‑4 to register Class A common stock to be issued in the transaction. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek approval. The filing includes standard forward‑looking statements cautions and directs investors to the SEC and company websites for the full materials.
Semler Scientific (SMLR) filed an 8-K announcing supplemental disclosures tied to its pending all-stock acquisition by Strive, Inc. The companies entered into a Merger Agreement on September 22, 2025. Semler furnished Exhibit 99.1, which provides additional information regarding Strive and is incorporated by reference.
Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement for Strive, a proxy statement for Semler, and a prospectus for Strive. A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek approval of the proposed transaction. The filing includes standard forward‑looking statement cautions and emphasizes that investors should review the S-4 and related materials for details on the transaction and related risks.
Semler Scientific filed a Rule 425 communication regarding a proposed acquisition by Strive, Inc.. The notice references social posts by Semler’s Director of Bitcoin Strategy and directs investors to official SEC materials for details.
Strive has filed a Form S-4 to register Class A common stock to be issued in the transaction, and a definitive information statement/proxy statement/prospectus will be sent to Semler stockholders to seek approval. The communication emphasizes where to access SEC filings and identifies potential solicitation participants.
It also states this is not an offer or solicitation and includes forward-looking statement cautions, noting that outcomes depend on various risks and uncertainties.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). The notice includes customary forward‑looking statements and cautions investors about uncertainties.
Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, which will include an information statement/proxy statement/prospectus. Semler Scientific stockholders will receive these materials to consider and vote on the deal. The communication states it is not an offer or solicitation to sell securities.
Semler Scientific issued a Rule 425 communication related to the proposed acquisition of Semler Sci by Strive, Inc.. The notice references social media posts by Semler’s Director of Bitcoin Strategy and directs investors to Strive’s filed Form S-4, which registers Class A common stock to be issued in the transaction and will include a combined information statement, proxy statement, and prospectus. A definitive proxy/prospectus will be sent to Semler stockholders to seek approval. The communication identifies potential proxy participants, states it is not an offer or solicitation, and includes forward‑looking statement cautions with references to risk factor filings.
Strive, Inc. filed a communication under Rule 425 regarding its proposed business combination with Semler Scientific (SMLR). The message, reposted on X.com by a Strive board member, includes a forward‑looking statements caution.
Strive intends to file a Form S-4 to register Class A common stock to be issued in the transaction, and an Information Statement/Proxy Statement/Prospectus will be sent to Semler stockholders to seek their approval. Related documents will be available on the SEC’s website and company investor sites. The notice also identifies potential “participants in the solicitation” and states this is not an offer or solicitation to sell securities.
Strive, Inc. released a Rule 425 communication about its proposed business combination with Semler Scientific, Inc.. The message, posted by Strive’s CEO on X, emphasizes forward-looking statement cautions and states Strive plans to file a Form S-4 to register Class A common stock to be issued in the transaction. Semler Scientific stockholders will receive an Information Statement/Proxy Statement/Prospectus to vote on the deal. The notice reiterates that this is not an offer or solicitation.
Strive, Inc. posted a Rule 425 communication about its proposed business combination with Semler Scientific (SMLR). Strive plans to file a Form S-4 to register Class A common stock to be issued in connection with the transaction.
A combined information statement, proxy statement, and prospectus will be sent to Semler stockholders to seek approval. Investors are urged to read these materials when available on the SEC’s website. The notice includes forward‑looking statement cautions and a clear no‑offer or solicitation disclaimer.
Strive, Inc. filed a Rule 425 communication about its proposed business combination with Semler Scientific. Strive plans to file a Form S-4 to register Class A common stock to be issued, which will include an information statement/proxy statement/prospectus.
A definitive proxy will be sent to Semler stockholders to seek approval. The communication includes forward-looking statements and clarifies it is not an offer or solicitation to sell securities.
FAQ
What is the current stock price of Semler Scientific (SMLR)?
What is the market cap of Semler Scientific (SMLR)?
